Report : North America Acne Medication Market Forecast to 2030 - Regional Analysis - by Therapeutic Class (Retinoids, Benzoyl Peroxide, Antibiotics, Salicylic Acid, and Others), Formulation (Topical Medication and Oral Medication), Type (Prescription Medicine and Over-the-Counter Medicine), Acne Type (Non-Inflammatory Acne and Inflammatory Acne), and Distribution Channel (Pharmacies and Drug Stores, Retail Stores, and E-Commerce)
At 4.6% CAGR, North America Acne Medication Market is Projected to be Worth US$ 4,794.01 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the North America acne medication market was valued at US$ 3,362.50 million in 2022 and is expected to reach US$ 4,794.01 million by 2030, registering a CAGR of 4.6% from 2023 to 2030. Increasing prevalence of severe acne and launch of novel drugs are among the critical factors attributed to the North America acne medication market expansion.
Severe acne, often characterized by painful cysts, nodules, and persistent inflammation, presents a considerable challenge that can significantly impact people's quality of life. As per the 2022 GBD research, acne has a prevalence rate of 9.4%, ranking it eighth among the most common diseases in the world. Acne vulgaris affects over 85% of young individuals from the age group of 12-25. Such a high prevalence has led to an upsurge in the demand for effective acne medications tailored to address moderate to severe forms of the condition. As individuals seek ways to mitigate the physical and emotional burden associated with severe acne, there is a corresponding increase in the demand for advanced and more effective prescription and over-the-counter treatments. This trend prompts pharmaceutical companies to focus on developing innovative formulations, including topical retinoids, oral antibiotics, hormonal therapies, and advanced topical treatments, to address the complex needs of individuals with severe acne. The Journal of Drugs in Dermatology (JDD) estimates that acne treatments incur over US$ 1 billion as direct annual costs to the US economy, with over-the-counter acne drugs accounting for nearly 10% of this cost. JDD also estimates that billions of dollars would be spent on acne treatment in the coming years. Thus, the increasing prevalence of severe acne and an upsurge in associated costs to economies bolster the North America acne medication market growth.
On the contrary, side effects associated with acne medication hampers the growth of North America acne medication market.
Based on therapeutic class, the North America acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held 33.5% share of the North America acne medication market in 2022, amassing US$ 1,125.28 million. It is projected to garner US$ 1,809.24 million by 2030 to expand at 6.2% CAGR during 2023-2030.
In terms of formulation, the North America acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held 68.7% share of the North America acne medication market in 2022, amassing US$ 2,311.17 million. It is estimated to garner US$ 3,414.72 million by 2030 to expand at 5.0% CAGR during 2023-2030.
By type, the North America acne medication market is bifurcated into prescription medicine and over-the-counter medicine. The prescription medicine segment held 65.2% share of North America acne medication market in 2022, amassing US$ 2,191.15 million. It is predicted to garner US$ 3,247.71 million by 2030 to expand at 5.1% CAGR during 2023-2030.
Based on acne type, the North America acne medication market is bifurcated into non-inflammatory acne and inflammatory acne. The inflammatory acne segment held 54.7% share of the North America acne medication market in 2022, amassing US$ 1,840.10 million. It is projected to garner US$ 2,689.65 million by 2030 to expand at 4.9% CAGR during 2023-2030.
In terms of distribution channel, the North America acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held 49.7% share of the North America acne medication market in 2022, amassing US$ 1,672.44 million. It is estimated to garner US$ 2,512.04 million by 2030 to expand at 5.3% CAGR during 2023-2030.
Based on country, the North America acne medication market is categorized into the US, Canada, and Mexico. The US held 85.6% share of North America acne medication market in 2022, amassing US$ 2,879.64 million. It is projected to garner US$ 4,130.04 million by 2030 to expand at 4.7% CAGR during 2023-2030.
Key players operating in the North America acne medication market are Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Almirall SA, Johnson & Johnson, Bausch Health Companies Inc, Centro Internacional de Cosmiatria SA de CV, Galderma SA, Pfizer Inc, GSK Plc, Viatris Inc, Somar Sapi De CV, and Italmex SA., among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com